Navigation Links
InterMune Reports Second Quarter 2008 Financial Results and Business Highlights
Date:7/31/2008

n its current fiscal year, which ends

on March 31, 2009.

ITMN-191 Program in HCV:

-- Assuming submitted abstracts will be accepted, InterMune expects to

present several abstracts on ITMN-191 at AASLD, scheduled for

October 31 - November 4 in San Francisco. These abstracts pertain

to various clinical studies on ITMN-191 and in-vitro studies of

ITMN-191 in combination with other direct antiviral compounds.

-- InterMune expects to announce top-line results from the currently

running 14-day study of ITMN-191 in combination with Pegasys and

ribavirin in the fourth quarter of 2008.

Conference Call and Webcast Details

InterMune will host a conference call today at 4:30 p.m. EDT to discuss its financial results for the second quarter 2008, its forward-looking financial guidance and its clinical development programs. Interested investors and others may participate in the conference call by dialing 888-799-0528 (U.S.) or 706-634-0154 (international), conference ID# 57393097. A replay of the webcast and teleconference will be available approximately three hours after the call.

To access the webcast, please log on to the company's website at http://www.intermune.com at least 15 minutes prior to the start of the call to ensure adequate time for any software downloads that may be required.

The teleconference replay will be available for 10 business days following the call and can be accessed by dialing 800-642-1687 (U.S.) or 706-645-9291 (international), and entering the conference ID# 57393097. The webcast will remain available on the company's website until the next earnings call.

About InterMune

InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and hepatology. InterMune has a pipeline portfo
'/>"/>

SOURCE InterMune, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. InterMune to Present at Thomas Weisel and Bear Stearns Healthcare Conferences
2. InterMune Announces Proposed Public Offering of Common Stock
3. InterMune Announces Pricing of $68 Million Public Offering of Common Stock
4. InterMune Announces Closing of Public Offering of Common Stock
5. InterMune Announces Fourth Quarter and Full Year 2007 Financial Results and Provides 2008 Guidance
6. InterMune to Present at the SIGnificant Options in Healthcare Conference
7. Evotec Expands Collaboration With InterMune
8. Statement by InterMune, Inc. Regarding Justice Department Action Against Former Employee for Past Conduct
9. InterMune to Present at Deutsche Bank Health Care Conference
10. InterMune to Present at Bank of America Health Care Conference
11. InterMune to Present at Citigroup Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... scientists are making progress in devising suitable means ... relies on quantum dotsa kind of artificial atom, ... new study demonstrates that changing the coupling of ... impulses can help better control them. This has ... quantum information units, which would produce faster quantum ...
(Date:7/24/2014)... Your cell phone may stay ... battery storage capacity. , New research indicates that ... created at Lawrence Livermore National Laboratory ... carbon components will perform as electrodes. , The ... need for higher-performance batteries. Several key characteristics of ...
(Date:7/24/2014)... , July 24, 2014  Neogen Corporation (Nasdaq: ... future forecasts of its potential revenue from new rodenticide ... to investors and analysts on July 22, 2014, Neogen,s ... analysts regarding this research. "It was my ... about the potential of a new type of rodenticide, ...
(Date:7/24/2014)... BETHESDA, Md. , July 24, 2014  Spherix ... to the fostering and monetization of intellectual property, today ... for the period ending June 30, 2014 on Monday, ... conference call at 10 a.m. ET on Monday, August ... to be led by the company,s CEO, Anthony ...
Breaking Biology Technology:Getting More Life out of Lithium-ion Batteries 2Neogen comments on SenesTech 2Spherix Schedules Shareholder Update Call 2
... ON, July 3 /PRNewswire-FirstCall/ - Vasogen Inc.,(NASDAQ: VSGN ... additional,restructuring plans to further reduce its cash burn ... strategic alternatives that may,include potential acquisitions and mergers. ... completed an extensive review of its VP,series of ...
... NEW BRUNSWICK, N.J., July 3 Senesco,Technologies, Inc. ... announced today,that it has contracted with Polyplus-transfection (Illkirch, ... of Senesco,s,combination therapy of siRNA against Factor 5A ... Senesco has previously reported positive preclinical in vivo ...
... 3 Antigen Discovery Inc. ("ADI",formerly ImmPORT Therapeutics ... advanced genomics and proteomics tools,announced today that the ... the,National Institute of Allergy and Infectious Diseases (NIAID) ... $3 million grant will,fund efforts to further develop ...
Cached Biology Technology:Vasogen Provides Corporate Update 2Senesco Signs a Supply Agreement for Polyplus-transfection's Delivery System 2Senesco Signs a Supply Agreement for Polyplus-transfection's Delivery System 3Senesco Signs a Supply Agreement for Polyplus-transfection's Delivery System 4Antigen Discovery Inc. Awarded a SBIR Phase II Grant to Commercialize Novel Antigens for Serodiagnostic Products and Vaccine Development 2
(Date:7/24/2014)... native animal species for food or commercial food sale, ... in the decline of many species of primates and ... more than half of the species being consumed are ... surveying not only the meat made available for sale ... forest by hunters and brought to villages for consumption, ...
(Date:7/24/2014)... a smog-free Los Angeles, where electric cars ply silent ... on heat from beneath the earth, from howling winds ... Stanford study finds that it is technically and economically ... powered by clean, renewable energy. Published in Energy ... inexpensive and reliable energy supply in California that could ...
(Date:7/24/2014)... multi-institutional team of researchers has developed a new nanoscale ... noninvasive method for assessing the function and properties of ... better diagnosis and treatment of gut diseases. ... bowel syndrome and inflammatory bowel disease all occur in ... in patients with diseases such as diabetes and Parkinson,s. ...
Breaking Biology News(10 mins):Stanford study shows how to power California with wind, water and sun 2Stanford study shows how to power California with wind, water and sun 3Stanford study shows how to power California with wind, water and sun 4New imaging agent provides better picture of the gut 2
... low levels of particulate air pollution may increase the ... suggest current exposure standards could be insufficient to protect ... public is exposed to ambient air pollution at the ... suggesting a potentially large public health impact," said Lynda ...
... People with highly developed emotional sensibilities are better at ... the Journal of Consumer Research. "Consumers who understand ... such as health decisions and product choices," explain the ... Childers (University of Kentucky). "A person can know a ...
... Medical Research, led by Jos Luis Milln, Ph.D., have ... replacement therapy to prevent hypophosphatasia (HPP), a primary skeletal ... foundation for future clinical trials for HPP patients. ... that most commonly results from a lack of vitamin ...
Cached Biology News:Even low levels of air pollution may pose stroke risk 2Potential therapy discovered for hypophosphatasia, a congenital form of rickets 2
Request Info...
... Quickly, effectively seals labware. Waterproof, moisture-proof ... anhydrous materials. Can be folded repeatedly ... rupturing. Stretched lengthwise at 21C (70F), ... when tension is removed, film only ...
...
Normal human AB serum, pooled...
Biology Products: